(Q40063676)

17 September 2017

Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver (English)

1 reference

17 September 2017

Samuel L Murphy

1

1 reference

17 September 2017

Hojun Li

2

1 reference

17 September 2017

Shangzhen Zhou

3

1 reference

17 September 2017

Alexander Schlachterman

4

1 reference

17 September 2017

Katherine A High

5

1 reference

17 September 2017

23 October 2007

1 reference

17 September 2017

1 reference

17 September 2017

16

1 reference

17 September 2017

1

1 reference

17 September 2017

138-145

1 reference

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

17 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Clinical gene transfer studies for hemophilia B.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Immunogenic issues concerning recombinant adeno-associated virus vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

A seroepidemiologic study of adenovirus-associated virus infection in infants and children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Epidemiology of adenovirus-associated virus infection in a nursery population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Local delivery of a viral vector mitigates neutralization by antiviral antibodies and results in efficient transduction of rabbit liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Intracellular trafficking of adeno-associated viral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Identification of a heparin-binding motif on adeno-associated virus type 2 capsids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Blood clearance rates of adenovirus type 5 in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Adeno-associated virus vectors can be efficiently produced without helper virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300334

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300334

1 reference

17 September 2017

1 reference